test
Friday, June 21, 2024

Eli Lilly’s Alzheimer’s drug to face safety, dosing scrutiny from FDA advisers 

Must read




When a Food and Drug Administration advisory panel meets Monday to size up an Eli Lilly experimental Alzheimer’s drug, questions about safety, selection of patients for treatment, and dosing will be at the fore, documents released Thursday show.



Source link

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article